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A mechanistic understanding of the pathophysiology underpinning psychiatric disorders is
essential for the development of targeted molecular therapies. For fragile X syndrome
(FXS), recent mechanistic studies have been focused on the metabotropic glutamate
receptor (mGluR) signaling pathway. This line of research has led to the discovery
of promising candidate drugs currently undergoing various phases of clinical trial, and
represents a model of how biological insights can inform therapeutic strategies in
neurodevelopmental disorders. Although mGluR signaling is a key mechanism at which
targeted treatments can be directed, it is likely to be one of many mechanisms contributing
to FXS. A more complete understanding of the molecular and neural underpinnings of the
disorder is expected to inform additional therapeutic strategies. Alterations in the assembly
of neural circuits in the neocortex have been recently implicated in genetic studies of autism
and schizophrenia, and may also contribute to FXS. In this review, we explore dysregulated
nitric oxide signaling in the developing neocortex as a novel candidate mechanism of
FXS. This possibility stems from our previous work demonstrating that neuronal nitric
oxide synthase 1 (NOS1 or nNOS) is regulated by the FXS protein FMRP in the mid-fetal
human neocortex. Remarkably, in the mid-late fetal and early postnatal neocortex of human
FXS patients, NOS1 expression is severely diminished. Given the role of nitric oxide in
diverse neural processes, including synaptic development and plasticity, the loss of NOS1
in FXS may contribute to the etiology of the disorder. Here, we outline the genetic and
neurobiological data that implicate neocortical dysfunction in FXS, review the evidence
supporting dysregulated nitric oxide signaling in the developing FXS neocortex and its
contribution to the disorder, and discuss the implications for targeting nitric oxide signaling
in the treatment of FXS and other psychiatric illnesses.
Keywords: cerebral neocortex, pyramidal neurons, neurodevelopmental disorders, nitric oxide signaling, Broca’s
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INTRODUCTION
Although a single locus genetic disorder, fragile X syndrome
(FXS), the leading inherited cause of intellectual disability (ID)
and monogenic syndromic form of autism spectrum disorder
(ASD), remains incompletely understood at the mechanistic level.
Since the identiﬁcation of FMR1 as the X-linked gene affected in
FXS (Warren et al., 1987; Oberlé et al., 1991; Verkerk et al., 1991;
Vincent et al., 1991), signiﬁcant research efforts have focused on
FMRP, the protein encoded by FMR1 (Ashley et al., 1993). FMRP
is an RNA-binding protein that controls the localization, stability,
and translation of neuronal mRNAs (Bagni and Greenough, 2005;
Zalfa et al., 2007; Bassell and Warren, 2008). It is highly expressed
in neurons and nearly ubiquitously present in the central nervous
system (Devys et al., 1993; Hinds et al., 1993; Bakker et al., 2000;
O’Donnell and Warren, 2002). Because FMRP is expressed in the
brain without preference for particular regions or neuronal sub-
types, its expression pattern does not provide insights into the
potential neural or neuronal substrates underlying the intellec-
tual and behavioral deﬁcits of the disorder. At the molecular level,
FMRP interacts with and controls the translation of a large num-
ber of neuronal mRNAs (Brown et al., 2001; Darnell et al., 2011),
estimated to be more than 800 transcripts. Consistent with the sig-
niﬁcant localization of FMRP to dendritic spines (Feng et al., 1997;
Antar et al., 2004; Gabel et al., 2004), which are specializations at
post-synaptic sites, many of these transcripts play key roles in
synapse formation and function (Brown et al., 2001; Darnell et al.,
2001, 2011; Miyashiro et al., 2003; Kindler andKreienkamp,2012).
The converging localization and function of many FMRP tar-
get mRNAs to the synapses has illuminated FMRP neurobiology;
however, precisely which of the myriad transcripts are mechanis-
tically most signiﬁcant for the psychopathology of FXS, or most
suitable as targets of molecular therapeutics, remains to be fully
explored.
One potential mechanism, coined the metabotropic glutamate
receptor (mGluR) theory of FXS, was proposed following obser-
vations linking mGluR signaling, long-term depression (LTD),
protein synthesis, and FMRP function (Weiler et al., 1997; Huber
et al., 2000, 2001, 2002) and has been a focus of recent basic and
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clinical research (Bear et al., 2004; Dölen et al., 2007; Ronesi and
Huber,2008; Berry-Kravis, 2014). At the timeof writing, drugs tar-
geting several molecular players in the mGluR signaling pathway
are being studied in clinical trials (Berry-Kravis, 2014; Erickson
et al., 2014; Jacquemont et al., 2014; Pop et al., 2014).
Since its original proposal, several lines of converging evidence
have corroborated the mGluR theory. The majority of the data
supporting excessive LTD in FXS is derived from studies of the
hippocampus (Huber et al., 2002; Bear et al., 2004), a critical brain
region for learning andmemory. The speciﬁc contributionof over-
active hippocampal LTD to the pathophysiology of FXS, however,
remains incompletely explored. Furthermore, the precise iden-
tities of the de novo proteins necessary for LTD have remained
largely mysterious, and they are likely to represent only a subset of
FMRP targets. Therefore, it is possible that additionalmechanisms
or brain regions are involved in the intellectual and behavioral
manifestations of FXS. Elucidating these mechanisms is expected
to uncover the neurobiology pertinent to FXS and provide novel
targets toward molecular therapy.
In this review, we explore disrupted nitric oxide (NO) sig-
naling as a new candidate mechanism of FXS centered in the
developing neocortex. In our recent work, we showed neuronal
nitric oxide synthase 1 (NOS1 or nNOS) to be translationally
regulated by FMRP in the fetal human neocortex and severely
reduced in the fetal and post-natal developing neocortex of FXS
patients (Kwan et al., 2012a). As NO is a multifunctional signal-
ing molecule with diverse neural functions, including synapse
development, neural transmission, and synaptic plasticity, the dis-
ruption of NOS1 protein translation in FXS may underlie the
pathogenesis of the disorder. Here, we (1) outline the genetic and
neurobiological data that implicate neocortical dysfunction in the
etiology of FXS; (2) review the evidence supporting dysregulated
NO signaling in the developing FXS neocortex and its potential
functional contribution to the disorder; and (3) discuss the impli-
cations for targeting NO signaling in the treatment of FXS and
other psychiatric disorders, including autism and schizophrenia
(SCZ).
NEOCORTICAL DYSFUNCTION AS A NEURAL BASIS OF FXS
Research into the mechanisms underlying FXS has long been
focused on the biology of FMRP, a key aspect of which is
centered on the identities of its mRNA targets (Brown et al.,
2001; Darnell et al., 2011). Although the number of direct
FMRP-interacting mRNAs is numerous and their individual
contributions to the disorder remain largely unknown, some
neurobiological aspects behind their function and dysfunction
have emerged. FMRP regulates the translation of many tran-
scripts encoded by genes implicated in ASD (Darnell et al.,
2011), and de novo mutations in ASD simplex families pref-
erentially affect genes encoding FMRP targets (Iossifov et al.,
2012). This convergence suggests that the pathophysiologies of
ASD and FXS may be mediated by common mechanisms, and
is consistent with the broad behavioral overlap between FXS
and autism (Rogers et al., 2001; Hagerman et al., 2010). Sim-
ilarly, genes disrupted by de novo variants in SCZ are also
signiﬁcantly enriched for those that encode FMRP target tran-
scripts (Fromer et al., 2014; Purcell et al., 2014). Although a
potential link between FXS and SCZ has not been extensively
explored, decreased FMRP levels have been associated with intel-
lectual deﬁcits and earlier onset in SCZ (Kovács et al., 2013).
Furthermore, recent ﬁndings have shown that the genetic under-
pinnings of ASD and SCZ exhibit signiﬁcant overlap (Carroll and
Owen, 2009; McCarthy et al., 2014). This putative mechanistic
intersection between FXS, ASD, and SCZ implicates a partial con-
vergence in the molecular and neural substrates underlying these
disorders.
Because FMRP is expressed in most neuronal subtypes from
early fetal development to aging (Abitbol et al., 1993; Devys et al.,
1993; Hinds et al., 1993; Kang et al., 2011), its spatiotemporal
expression pattern does not implicate any particular neural struc-
ture or developmental stage to be especially important to the
etiology of the disorder. Recent advances in the ﬁelds of ASD
and SCZ genetics have, however, begun to reveal the neuro-
biology and neural substrates that underlie complex disorders
of brain development. Historically, the genetic heterogeneity of
ASD, SCZ, and other psychiatric diseases has been a major chal-
lenge in identifying the genetic loci that carry deﬁnitive genetic
risk. Ironically, the large number of risk loci that has impeded
progress may now provide an opportunity to better pinpoint the
neural substrates and developmental stages that are central to
the pathophysiology of these disorders (State and Šestan, 2012).
Because of the pleiotropic nature of gene function, the major-
ity of genes in mammalian genomes are expressed in multiple
organs over multiple time points during the development, matu-
ration, and agingof theorganism.Accordingly, expression analyses
of ASD or SCZ risk genes using comprehensive spatiotempo-
ral transcriptomic data from the human brain (Johnson et al.,
2009; Colantuoni et al., 2011; Kang et al., 2011), have revealed
highly disparate spatial patterns and developmental trajectories.
However, gene co-expression network analyses, which can be
used to identify clusters of highly correlated genes (Eisen et al.,
1998; Stuart et al., 2003; Geschwind and Konopka, 2009), have
uncovered key points of convergence in the timing and location
of risk gene expression. Expression network analyses of high-
conﬁdence ASD loci have identiﬁed the mid-fetal neocortex to
be a signiﬁcant point of spatiotemporal intersection (Parikshak
et al., 2013; Willsey et al., 2013), suggesting a signiﬁcant contri-
bution of the developing neocortex to ASD circuit dysfunction
(Kwan, 2013). In SCZ, a similar analysis has also implicated
the fetal frontal neocortex (Gulsuner et al., 2013). Mid-gestation
is a critical developmental period during which key neocortical
axon tracts are being established prior to the onset of signiﬁcant
synaptogenesis (Figure 1; Kang et al., 2011). This convergence
of ASD and SCZ gene expression, therefore, strongly implicates
miswiring of neocortical circuits in the pathophysiology of these
neurodevelopmental disorders.
Neocortical dysfunction may similarly contribute to FXS eti-
ology. The neocortex underlies conscious experience, thoughts,
and actions in mammals, and is the seat of higher cognitive
functions including speech and language and social cognition
(Geschwind and Rakic, 2013), which are often affected in FXS
and other neurodevelopmental disorders. The proper function-
ing of the neocortex depends on the precise wiring of its
neural circuits during fetal and early post-natal development.
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FIGURE 1 | Trajectories of NOS1 and FMR1 expression and key
developmental events in the mid-fetal human neocortex.The
approximate timing and duration of selected neocortical developmental
processes, as deﬁned by anatomical ﬁndings, are illustrated (Bourgeois, 1997;
de Graaf-Peters and Hadders-Algra, 2006; Clancy et al., 2007; Workman et al.,
2013). FMR1 (blue) is widely expressed in the brain from early fetal
development into adult aging. During the mid-fetal ages, periods 4–6 (Kang
et al., 2011), NOS1 is expressed in the pyramidal neurons of Broca’s area L5
(red) and ACC L2/L3 (green) (Kwan et al., 2012a). Unlike its transient pyramidal
expression, NOS1 is expressed in interneurons from fetal development to
late adulthood. Supporting a potential role in neuropsychiatric disorders,
mid-fetal neocortical development has been recently implicated in analyses of
gene co-expression networks of ASD- and SCZ-associated genes (Gulsuner
et al., 2013; Parikshak et al., 2013; Willsey et al., 2013).
Dysregulation of neocortical circuit assembly and function has
long been thought to contribute to neuropsychiatric disorders.
In FXS, cognitive and language development are delayed or
impaired (Abbeduto et al., 2007), phenotypes that are consis-
tent with disrupted neocortical function. With 30% of FXS
patients meeting the full diagnostic criteria for autism and an
additional 30% falling elsewhere on the autism spectrum (Har-
ris et al., 2008), deﬁcits in social cognition, another higher
function centered in the neocortex, are also a key impair-
ment in FXS. Anatomically, this possibility is further sup-
ported by ﬁndings that revealed altered dendritic spine mor-
phologies in the neocortical pyramidal neurons of human FXS
patients and Fmr1 null mice (Comery et al., 1997; Irwin et al.,
2000).
With recent advances in neuroimaging, deﬁcits in neural
connectivity are being mapped and alterations in neocortical
circuitry have been reported in multiple disorders, including
ASD, SCZ, and bipolar disorder (Kuperberg et al., 2008; Henin
et al., 2009; Henseler et al., 2010; Hall et al., 2013; Zikopoulos
and Barbas, 2013). Functional and anatomical imaging studies
have also supported neocortical dysfunction in FXS. One anal-
ysis found that, during the counting Stroop interference task,
normal activation in the inferior/middle frontal gyrus and infe-
rior/superior parietal lobe was absent, and an aberrant activation
in the anterior region of the prefrontal cortex (PFC) was present
instead (Tamm et al., 2002). In the Go/NoGo task, FXS patients
exhibited abnormal activation patterns in multiple brain regions,
including signiﬁcantly reduced activation in the supplementary
motor area and anterior cingulate cortex (ACC; Menon et al.,
2004). Furthermore, white-matter abnormalities were found in
frontostriatal circuitry (Haas et al., 2009), and a recent anal-
ysis of functional connectivity and large-scale brain networks
in FXS revealed widespread reductions in neocortical connec-
tivity (Hall et al., 2013). Interestingly, maturation of the PFC
was found to be aberrant in adolescent FXS patients, an alter-
ation that is correlated with delayed cognitive maturation (Bray
et al., 2011). The PFC, often considered to be the prototypical
center of higher-order cognitive processing, is critical to work-
ing memory, executive function, and inhibition, and has been
robustly implicated in multiple psychiatric disorders (Weinberger
et al., 1986; Goldman-Rakic, 1996; Miller et al., 2002). Together,
these lines of evidence converge on the possibility that alter-
ations in neocortical circuitry underlie some aspects of FXS
pathogenesis. The molecular mechanisms that may contribute
to these alterations in FXS, however, have not been extensively
explored.
FMRP REGULATION OF NOS1 TRANSLATION IN THE HUMAN
FETAL NEOCORTEX
Recently, we identiﬁed neuronal NOS1 or nNOS to be a novel
FMRP target mRNA in the mid-fetal human neocortex (Kwan
et al., 2012a). This interaction was mediated by two G-quartet
motifs within the coding region of human NOS1 that are neces-
sary and sufﬁcient for FMRP binding. Consistent with a direct
interaction, FMRP was found to be a positive regulator of NOS1
translation, controlling NOS1 protein levels in a dose-dependent
manner in vitro and in vivo. FMRP is mostly known to be a trans-
lation repressor through a ribosome stalling mechanism that was
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elegantly shown using an in vitro system (Darnell et al., 2011). In
some cases, it has been shown to function as a positive transla-
tional regulator (e.g., SOD1, ASCL1 (hASH1), Kcnd2 (Kv4.2), and
DLG4 (PSD95)) (Todd et al., 2003; Bechara et al., 2009; Fähling
et al., 2009; Gross et al., 2011), and may mediate this translational
control in a context- or activity-dependent manner.
Interestingly, FMRP binding and regulation of NOS1 is species-
dependent, being present in primate species, which exhibit
conserved G-quartet sequences in NOS1, but absent in rodent
species, which lack the NOS1 G-quartets. Consistent with this
species difference, NOS1 has not been previously identiﬁed in the
mouse brain to be an FMRP target mRNA (Brown et al., 2001;
Darnell et al., 2011). The absence of the G-quartet motifs from
rodent Nos1 and the high degree of amino acid identity in FMRP
among mammals suggest that the interaction between FMRP and
NOS1 evolved via changes in the NOS1 sequence, as opposed to
changes in FMRP function. This suggests the possibility of addi-
tional examples of evolutionary changes that can impact FMRP
interaction with target mRNAs. Indeed, consistent with this pos-
sibility, a recent analysis of brain-expressed exons under purifying
selection demonstrated enrichment for ASD-associated genes and
ASD-relevant FMRP targets (Uddin et al., 2014).
The dose-dependence upregulation of NOS1 translation by
FMRP in the normal human neocortex suggests the possibility
of disrupted NOS1 protein synthesis in human FXS patients.
Examination of FXS patient brains revealed, remarkably, that
NOS1 is absent from the neocortex at fetal ages, and signiﬁ-
cantly decreased in the neocortex during postnatal development
(Figure 2). Although a large number of FMRP target mRNAs
have been identiﬁed in the mouse brain (Brown et al., 2001; Dar-
nell et al., 2011), the majority of these transcripts have not been
assessed for potential translational dysregulation in FXS patient
materials. Therefore, NOS1 represents the ﬁrst mRNA that is
found to interact with FMRP in the fetal human brain and trans-
lationally disrupted in the developing FXS patient brain. NOS1 is
an enzyme that mediates the tightly-regulated biosynthesis of NO,
FIGURE 2 | Immunoblot analysis of NOS1 expression in the developing
neocortex. In the developing neocortex, the expression levels of NOS1
(red arrowhead) are severely reduced in human FXS patients. This loss is
species-dependent. NOS1 levels are unaltered in the neocortex of neonatal
Fmr1 null mice, an animal model of FXS. Adapted from Kwan et al. (2012a).
a multifunctional gaseous signaling molecule (Bredt and Snyder,
1994; Garthwaite, 2008). Given the key role of NO in diverse neu-
ral processes including synaptic plasticity, retrograde signaling,
development, excitotoxicity, and mental health (Brenman et al.,
1996; Hölscher, 1997; Contestabile, 2000; Calabrese et al., 2007;
Garthwaite, 2008; Steinert et al., 2010), the loss of NOS1 in the
developing FXS neocortex may contribute to the pathophysiol-
ogy of the disorder. Here, we assess disrupted NO signaling as
a candidate mechanism underlying FXS, focusing on the highly
speciﬁc spatiotemporal expression pattern of NOS1 in the fetal
human neocortex and the potential neurobiological contribution
of disrupted NO signaling to FXS and other neurodevelopmental
disorders.
SPATIOTEMPORAL AND SPECIES-DEPENDENT EXPRESSION
OF NOS1 IN THE HUMAN NEOCORTEX
To determine the potential contribution of NOS1 to FXS, it is
necessary to consider the time and location of NOS1 function
during brain development. In contrast to the widespread expres-
sion of FMRP, NOS1 expression exhibits spatial, temporal, and
neuronal subtype speciﬁcity, providing insights into its potential
neural function. In the neocortex of several mammalian species,
NOS1 has been known to be a selective marker of inhibitory
interneurons (Vruwink et al., 2001) while being absent from the
principal neurons of the neocortex, the excitatory projection
(pyramidal) neurons. In the human mid-fetal (13–24 weeks post-
conception; Figure 1) neocortex, however, we found NOS1 to
be present not only in the interneurons, but also in the pyrami-
dal neurons of two speciﬁc neocortical areas underlying higher
cognitive functions: the fetal Broca’s area and orofacial motor
cortex, and the ACC (Figure 3; Kwan et al., 2012a). The pyrami-
dal projection neurons occupy a central position in neocortical
circuitry, being the source of long distance axonal projections
that connect distal areas within the neocortex (via intracortical
connections) and the neocortex with subcortical brain structures
(via corticofugal connections). The newly identiﬁed pyramidal
expression of NOS1 is particularly surprising because pyramidal
neurons are derived from distinct progenitors and have greatly
divergent chemical and electrophysiological properties compared
to interneurons (Markram et al., 2004; Kwan et al., 2012b). Inter-
estingly, the expression of NOS1 in the human neocortex sharply
contrasts that in the mouse neocortex, wherein NOS1 is exclu-
sively present in inhibitory interneurons (Figure 3; Kwan et al.,
2012a). NOS1 expression analysis in the fetal macaque neocor-
tex and sequence conservation analysis in mammals revealed that
pyramidal NOS1 expression is likely to be primate-speciﬁc. The
recent origin of this expression pattern is consistent with the pos-
sibility that pyramidal NOS1 plays a key role in the development
or function of neocortical circuitry underlying higher cognitive
functions.
In addition to this notable spatial selectivity, NOS1 expression
in the human neocortex further exhibits remarkable temporal
speciﬁcity, occurring only transiently within a small mid-fetal
window and becoming dramatically downregulated by late ges-
tation (Figures 1 and 3). During this mid-gestation period, the
genesis of neocortical pyramidal neurons is largely complete and
the deep neocortical layers have been formed,whereasmany upper
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FIGURE 3 | Species-dependent NOS1 expression in the developing
neocortex. (A) In the mid-fetal human neocortex, NOS1 is speciﬁcally
expressed in the pyramidal neurons of two neocortical regions underlying
language and cognitive functions. In the Broca’s area (red boxes), NOS1
expression (blue), is selectively present in the pyramidal neurons of
neocortical layer 5 (L5). NOS1-expressing neurons are assembled into
minicolumns (red asterisks) separated by NOS1-negative neurons. In the
anterior cingulate cortex (ACC; green boxes), many L2/L3 pyramidal neurons
express high levels of NOS1. NOS1 expression in interneurons (open
arrowheads) is present throughout neocortical areas and layers with no
signiﬁcant selectivity. (B) In the early-postnatal mouse neocortex, which is
developmentally equivalent to the human mid-fetal neocortex, NOS1 is
exclusively expressed in interneurons (open arrowheads) and absent from
pyramidal neurons.
layers neurons are migrating toward their laminar destination.
Importantly, neocortical axon tracts are undergoing outgrowth
to reach their target destinations, a process that largely precedes
the onset of peak synaptogenesis (Hadley et al., 1983; Kang et al.,
2011; Xu and Henkemeyer, 2012). Overall, the spatiotemporal
speciﬁcity of pyramidal NOS1 expression is consistent with a
key role for NOS1 in the formation of speciﬁc neocortical cir-
cuits important for higher cognition. The location, connectivity,
and neural function of these circuits provide crucial insights into
the potential consequences of NOS1 dysregulation in the FXS
neocortex.
BROCA’S SPEECH AND LANGUAGE AREA AND OROFACIAL
MOTOR CORTEX
In the mid-gestation frontal and frontoparietal operculum, the
fetal anlage of the adult Broca’s speech and language area and
orofacial motor cortex, NOS1 is speciﬁcally expressed in layer
5 (L5) corticofugal projection neurons, the output neurons
of the neocortex (Figure 3; Kwan et al., 2012a). Broca’s area,
located in the inferior frontal gyrus, plays a key role in the
generation of speech and is also important in language com-
prehension (Judas and Cepanec, 2007; Keller et al., 2009). The
L5 expression of NOS1 in the fetal Broca’s area is develop-
mentally regulated, being exclusively present from approximately
16 to 24 weeks post-conception. The expression of NOS1 in
these neurons during the 7–8 week fetal window when they
differentiate and acquire their axonal connectivities implies a role
for NOS1 in the assembly of motor circuits involved in speech
and language. Several lines of evidence, including studies of
gene co-expression, microscopic neuroanatomy, and functional
imaging, point to a putative contribution of disrupted NOS1
expression in Broca’s area to the psychopathology of FXS and pro-
vide insights into the potential mechanistic underpinnings of this
disruption.
In the mid-fetal Broca’s area, NOS1 neurons coexpress BCL11B
(previously CTIP2), a transcription factor that is speciﬁcally
expressed in and required for the development of corticofugal
projection neurons (Arlotta et al., 2005). This coexpression is con-
sistent with the L5 pyramidal identity of NOS1 neurons and a
potential role for NOS1 in neocortical output circuits originat-
ing from this area. Abnormal activation of the inferior frontal
gyrus, which encompasses the Broca’s area, in FXS patients dur-
ing the counting Stroop interference task (Tamm et al., 2002)
has suggested altered Broca’s area connectivity in the disorder.
Furthermore, functional imaging studies of ASD patients have
identiﬁed speciﬁc alterations in Broca’s area connections. For
example, in a recent analysis of network connectivity in 24-
month old ASD infants, alterations in network efﬁciencies were
reported in all four cortical lobes, with a signiﬁcant reduc-
tion in the Broca’s area in the frontal lobe (Lewis et al., 2014).
Importantly, reduced network efﬁciency in Broca’s area corre-
lated with increased ASD symptom severity. In another recent
study, naturally sleeping ASD toddlers exhibited signiﬁcantly
weakened interhemispheric correlations in the inferior frontal
gyrus (Dinstein et al., 2011). Interestingly, the strength of the
interhemispheric synchrony was negatively correlated with autism
severity and positively correlated with verbal ability. Further-
more, a reversal in volume asymmetry in the Broca’s area has
been reported in autistic boys (De Fossé et al., 2004), implicating
both structural and functional differences in this area in ASD. It
remains to be shown whether NOS1 contributes to Broca’s area
alterations in ASD or similar alterations in FXS. The highly spe-
ciﬁc spatiotemporal expression of NOS1, however, is consistent
with this possibility.
In the mid-fetal Broca’s area, NOS1 neurons coexpress FOXP2
(Kwan et al., 2012a), a gene altered in a severe speech disorder (Lai
et al., 2001; Fisher and Scharff, 2009) and implicated in ASD and
cognitive impairments (Bacon and Rappold, 2012). The presence
of NOS1 in FOXP2-expressing neurons adds further support to a
possible role of NOS1 in ASD and cognitive neural circuits. Fur-
thermore, NOS1-expressing neurons are organized into microcir-
cuits known asminicolumns (Figure 3; Kwan et al., 2012a), a verti-
cal arrangement thought to constitute a functional unit of cortical
circuitry (Mountcastle, 1997; Buxhoeveden and Casanova, 2002).
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Interestingly, the arrangement of minicolumns is disorganized
in psychiatric disorders, including ASD and SCZ, potentially
contributing to circuit dysfunction by disrupting the inhibitory
architecture of the neocortex (Buxhoeveden and Casanova,
2002; Casanova et al., 2002, 2003). The expression of NOS1
in minicolumns during fetal development is consistent with
a role for NO in the assembly of microcircuitry, possibly
related to ASD and SCZ, in this distinctly human neocortical
area.
ANTERIOR CINGULATE CORTEX
In addition to the Broca’s area, a second neocortical region
with important cognitive functions also exhibit pyramidal NOS1
expression during mid-fetal development. Starting from approx-
imately 16 weeks post-conception, NOS1 is expressed in a large
number of upper-layer (L2–L3) intracortical projection neu-
rons of the ACC at signiﬁcantly higher levels compared to the
L5 neurons of the Broca’s area (Kwan et al., 2012a). NOS1-
expressing neurons in the ACC, in contrast to those in the
Broca’s areas, are not marked by BCL11B but instead coexpress
SATB2, a transcription factor that labels intracortical projec-
tion neurons and is required for their normal development
(Alcamo et al., 2008; Britanova et al., 2008). Unlike the corticofu-
gal projection neurons that express NOS1 in the Broca’s area,
NOS1-expressing pyramidal neurons in the ACC are likely to
contribute to intracortical connectivity. Furthermore, although
NOS1 expression in ACC pyramidal neurons is also temporally
regulated, its timing spans a lengthier period during develop-
ment, being present at high levels from mid- to late- gestation
and downregulated after birth (Kwan et al., 2012a). Whereas
no pyramidal neurons retain NOS1 expression in the postna-
tal Broca’s area, a small number of pyramidal neurons in the
ACC express low levels of NOS1 into adulthood (Gao et al.,
2013). The signiﬁcance of NOS1 expression in adult pyrami-
dal neurons and whether its function parallels its fetal role
remains to be explored. The ACC is not only highly intercon-
nected to cognitive and emotional circuits, but also important
in a number of neuropsychiatric diseases (Devinsky et al., 1995).
Functional imaging, gene expression analyses, and other studies
suggest the possibility that NOS1-expressing pyramidal neurons
in the ACC may contribute to the psychopathology of FXS
in a manner distinct from their counterparts in the Broca’s
area.
Centrally positioned in the neocortex, the ACC is a key point of
integration for cognitive and emotional processes, playing a cru-
cial role in executive, social, and affective functions (Devinsky
et al., 1995). The ACC exhibits extensive intracortical connec-
tivities. The dorsal cognitive portion of the ACC is connected
with motor and sensory systems of the neocortex, and is there-
fore well-positioned to integrate sensory stimuli with top-down
commands (Paus et al., 1993; Picard and Strick, 1996; Williams
et al., 2004; Crottaz-Herbette and Menon, 2006). The ventral part
of the ACC, which is involved in emotion and motivation pro-
cessing, is connected with the anterior insula and amygdala, as
well as the nucleus accumbens and hypothalamus (Bush et al.,
2002; Etkin et al., 2011). Functional imaging studies have found
the ACC to be important for performance monitoring, error
detection, action selection, and reinforcement of adaptive behav-
ior (Brown and Braver, 2005; Schweimer and Hauber, 2006; Ko
et al., 2009). Alterations in ACC circuitry have been proposed
to contribute to maladaptive behaviors in psychiatric disorders
(Drevets et al., 2008; Davey et al., 2012; Tu et al., 2012; Zikopoulos
and Barbas, 2013). The expression of NOS1 in the intracortical
projection neurons of the ACC implicates NOS1 in the connec-
tivity of cognition and emotion circuits, which likely underlie
some aspects of the pathogenesis in a number of neuropsychiatric
disorders.
Data from several studies lend indirect support to a poten-
tial role of ACC NOS1 dysregulation in FXS. Studies of a human
NOS1 hypomorphic allele revealed homozygosity to be associated
with attention deﬁcit hyperactivity disorder (ADHD), impulsivity,
and aggression (Reif et al., 2009), linking reduced NOS1 activity to
behavioral features often comorbid with FXS (Rogers et al., 2001).
This NOS1 hypomorphism has also been linked to reduced neural
activity in the ACC (Reif et al., 2009), consistent with a potential
role of NOS1 in the development of ACC connectivity. Additional
functional imaging studies revealed a similar reduction in ACC
activation in FXS and ADHD patients during attentional pro-
cessing tasks (Bush et al., 1999; Uddin and Menon, 2009) and in
autistic children in response to a familiar face (Pierce and Red-
cay, 2008). The convergence of neural and behavioral deﬁcits
between NOS1 hypomorphism, FXS, and FXS comorbidities pro-
vide robust support to the possibility of a functional role of NOS1
in the development and function of ACC circuitry related to FXS
and ASD.
In addition to FXS and ASD, ACC dysfunction has also been
associated with other psychiatric disorders. In SCZ, pathological
studies have found neuronal architecture to be altered in the ACC
(Salgado-Pineda et al., 2014), whereas neural imaging studies have
found abnormalities in the ACC that were reversed with treat-
ment response. In major depressive disorder, neuronal density was
found to be reduced in the ACC (Rajkowska et al., 1999, 2001) and
psychotherapy success was found to correlate with increased ACC
activity (Mayberg et al., 1997; Quidé et al., 2012). Interestingly, a
recent study of depressive patient materials revealed a signiﬁcant
reduction in NO metabolites in the cerebrospinal ﬂuid (Gao et al.,
2013). Furthermore,NOS1 expression in thepyramidal neurons of
the adult ACC was found to be signiﬁcantly reduced in depressed
patient brains (Gao et al., 2013). Although FXS has not been asso-
ciated with major depression, de novo variations in SCZ have been
shown to preferentially affect FMRP targets and FMRP levels have
been correlated with SCZ severity (Kovács et al., 2013; Fromer
et al., 2014; Purcell et al., 2014), suggesting a potential mechanistic
overlap.
The spatiotemporal expression pattern of NOS1 during circuit
wiring is consistent with a potential role in establishing global
connectivity during neocortical development. By imaging resting
state coordinated activity between brain areas, a measure of func-
tional connectivity can be inferred based on synchronous activity
(Power et al., 2011). Remarkably, Broca’s area and the ACC, the
two neocortical areas with signiﬁcant mid-fetal pyramidal NOS1
expression, exhibit coordinated activity and are known to form a
cingulo-opercular network (Power et al., 2011), one of the default
mode networks of the neocortex (Vaden et al., 2013; Sestieri et al.,
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2014). Interestingly, a disruption in the activity of the cingulo-
opercular network has been identiﬁed in SCZ (Tu et al., 2012).
Although the cingulo-opercular networkhas not been examined in
individuals with the hypomorphic NOS1 allele, these data suggest
a potential contribution of reduced NOS1 activity to the altered
connectivity of a default mode network. Together, these ﬁndings
converge on the possibility that NOS1 dysfunction in pyramidal
neurons of the ACC and Broca’s area may contribute to distinct
psychiatric disorders that affect higher cognitive abilities.
A FUNCTIONAL CONVERGENCE ON SYNAPTIC
MECHANISMS
Recent advances in psychiatric genetics have reafﬁrmed the het-
erogeneity of disease loci and the complexity of these disorders.
However, a functional convergence has emerged from many of
these studies. In ASD, speciﬁc functional subclasses of risk loci
have been identiﬁed based on gene ontology and network analysis
(Krumm et al., 2014; Pinto et al., 2014). These unbiased analy-
ses have revealed chromatin biology and synaptic function to be
key processes in ASD. Furthermore, empirical evidence has also
indicated that the behavioral and intellectual deﬁcits present in
ASD, and often comorbid with FXS, likely reﬂect an underlying
defect in synaptic development, plasticity, or function (Zoghbi,
2003; Garber, 2007). Interestingly, similar analyses of SCZ genes
have identiﬁed a number of shared risk loci, particularly in chro-
matin modiﬁers and synaptic molecules (McCarthy et al., 2014).
The emerging data have shown many of the synaptic genes asso-
ciated with ASD or SCZ to encode mRNA transcripts regulated
by FMRP (Darnell et al., 2011; Iossifov et al., 2012; Fromer et al.,
2014; Purcell et al., 2014). Furthermore, synaptic dysregulation
is now recognized as a key pathology in a number of psychi-
atric disorders, suggesting the synapse to be a common neural
substrate underlying distinct clinical manifestations of cognitive
impairment (Penzes et al., 2011).
From the earliest functional studies, it has been clear that FXS
involves deﬁcits at the synapse. Alterations in spine morphology is
well-characterized in humanFXS (Comery et al., 1997) and animal
models of FXS (Irwin et al., 2000; Nimchinsky et al., 2001), with
both presenting signiﬁcantly more morphologically immature
spines and fewer mature spines. Similar deﬁcits in spine mor-
phology and synapse function have been reported to be present
in ASD (Kaufmann and Moser, 2000; Hutsler and Zhang, 2010;
Penzes et al., 2011). The localization of FMRP to dendritic spines
and the putative function of many of its target mRNAs at or near
synaptic contacts add further support to the possibility that FXS
is a disorder of synaptic development and function (Irwin et al.,
2000; Huber et al., 2002; Bear et al., 2004).
Consistentwith a putative contributionof dysregulatedNOsig-
naling to FXS pathophysiology, NOS1 is likely to have a synaptic
function as well. Subcellularly, NOS1 is signiﬁcantly localized to
the dendritic spines (Burette et al., 2002; Kwan et al., 2012a). This
localization ismediated by direct interactionwith the PDZdomain
of post-synaptic density protein PSD-95 (Brenman et al., 1996).
The catalytic activity of NOS1 requires Ca2+ inﬂux,which is under
the control of near byNMDAreceptors (Brenman andBredt, 1997;
Sattler et al., 1999). Interestingly, blockade of NOS1 function has
been shown to disrupt synapse formation and result in spine loss
(Sánchez-Islas and León-Olea, 2004; Morales-Medina et al., 2007;
Nikonenko et al., 2008). Therefore, aspects of spine morphology
deﬁcits in FXS may originate from a loss of NO signaling. Over-
all, given the key role of synaptic proteins in ASD, NOS1 is well
positioned to mediate at least some of the mechanisms disrupted
in FXS (Figure 4).
NITRIC OXIDE SIGNALING AS A TARGET FOR FXS
MOLECULAR THERAPIES
The development of molecular therapeutic interventions for neu-
rodevelopmental disorders represents an immense challenge. In
the past decades, these efforts have been impeded by the tremen-
dous phenotypic and genotypic heterogeneity in the patient
populations, the lack of speciﬁc knowledge on the molecular path-
ways, brain regions, or developmental timepoints most relevant to
the pathophysiology of the disorders, and the identiﬁcation of
the appropriate primary endpoints (Haddad and Dursun, 2008;
Jacquemont et al., 2014). Recent advances in psychiatric genet-
ics have helped to pinpoint some of the molecular and neural
underpinnings of these disorders, and revealed potential tar-
gets for therapeutic interventions. These strategies have focused
mainly on alterations in molecular signaling pathways, which
may be more targetable compared to structural deﬁcits in brain
development.
Since the proposal of the mGluR theory (Bear et al., 2004;
Pop et al., 2014), a number of therapies targeting molecules up
or downstream of mGluR signaling have been developed and
reached various phases of clinical trial. For example, an open
label trial of fenobam(NPL-2009), anmGluR5 antagonist, amelio-
rated anxiety, hyperarousal, anddeﬁcits in prepulse inhibition, and
improved continuous performance task outcomes (Berry-Kravis
et al., 2009). Arbaclofen (STX209), a GABA receptor agonist acting
upstream of mGluR signaling, showed mixed promise in correct-
ing behavioral problems, which was strengthened when adjusted
for baseline severity of social withdrawal (Berry-Kravis et al., 2012;
Erickson et al., 2014; Jacquemont et al., 2014). The mGluR antag-
onist mavoglurant (AFQ056) has shown some promise in patients
with complete methylation at the FMR1 promoter and in an
animal model of FXS (Jacquemont et al., 2011; Gantois et al.,
2013). The commercial futures of arbaclofen and mavoglurant,
however, are unclear, due to the recent discontinuation of their
development.
The possibility of dysregulated NO signaling in FXS may lead
to novel therapeutic strategies, including those that increase the
brain levels of NO or cyclic guanosine monophosphate (cGMP),
a second messenger elevated downstream of NO-mediated activa-
tion of soluble guanylate cyclase (sGC; Garthwaite and Boulton,
1995). Phosphodiesterase (PDE) inhibitors and NO donors have
been used to enhance cGMP at distinct points of the NO signal-
ing pathway. PDE type 5 inhibitors, which elevate cGMP levels
by blocking their enzymatic degradation, are well known for their
role in treating erectile dysfunction (Boolell et al., 1996; Sandner
et al., 2008), but may have additional indications in the brain.
Sildenaﬁl has been shown to have antidepressant, anxiolytic, and
cognitive effects, and to increase cGMP levels in the hippocam-
pus (Rutten et al., 2005; Liebenberg et al., 2010, 2012; Uthayathas
et al., 2013; Zhang et al., 2013). Tadalaﬁl has similar antidepressant
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FIGURE 4 | A functional convergence on synaptic mechanisms. (A) Many
ASD-associated genes are localized to the synapse, robustly implicating
synaptic dysfunction in ASD. Adapted from Peça et al. (2011). (B) NOS1 is
anchored to the post-synaptic member via interactions with PSD-95
(Brenman et al., 1996), and therefore, well-positioned to contribute to the
synaptic mechanisms underlying FXS and ASD.
and anxiolytic effects, and has additionally been shown to reverse
cognitive dysfunctionby crossing the blood–brain barrier (Lieben-
berg et al., 2010, 2012; García-Barroso et al., 2013). cGMP levels
may also be increased using NO donors to stimulate sGC activ-
ity. One such donor is sodium nitroprusside, a single intravenous
administration of which has been shown to rapidly ameliorate
the positive, negative, anxiety, and depressive symptoms in SCZ
patients (Hallak et al., 2013). Interestingly, NO donors may medi-
ate effects in addition to sGC activation. For example, the NO
donorminocycline is known to inhibitmatrixmetalloproteinase-9
(MMP9), a protein encoded by an FMRP target mRNA (Berry-
Kravis, 2014). It also promotes spine maturation and normal
behavior in Fmr1 null mice (Bilousova et al., 2009) and delivers
a signiﬁcant improvement in anxiety and mood-related behaviors
in children diagnosed with FXS (Paribello et al., 2010; Leigh et al.,
2013). Additional drugs may more directly target NOS1 func-
tion or expression. For example, sapropterin, a synthetic form
of the NOS cofactor tetrahydrobiopterin, was found to improve
behavioral symptoms of ASD (Frye et al., 2013). A drug currently
undergoing clinical trials for FXS and Rett syndrome may also
affect NOS expression. NNZ-2566, a GPE peptide analog has been
previously demonstrated to increase neuronal ChAT, GAD, and
NOS expression (Guan et al., 1999; Guan and Gluckman, 2009;
Berry-Kravis, 2014). Further studies on these and other therapies
targeting NOS are expected to reveal the feasibility and efﬁcacy of
this line of treatment strategy for FXS and ASD.
NO SIGNALING IN MULTIPLE PSYCHIATRIC DISORDERS
Emerging genetic studies of multiple psychiatric disorders pre-
viously thought to be mechanistically distinct have implicated
the same set of genes to carry disease risk for each disorder.
A recent analysis of de novo variants uncovered shared genetic
underpinnings in ASD and SCZ (McCarthy et al., 2014). In
a recent large genome-wide association study (GWAS), risk is
correlated across ﬁve psychiatric disorders: ASD, SCZ, atten-
tion deﬁcit-hyperactivity disorder, bipolar disorder, and major
depressive disorder (Smoller et al., 2013). Remarkably, from this
pooled analysis, single nucleotide polymorphisms (SNPs) within
two L-type voltage-gated calcium channel (VGCC) subunits,
CACNA1C and CACNB2, surpassed statistical threshold. This
and previous studies associating CACNA1C with the individ-
ual disorders [Splawski et al., 2006; Ferreira et al., 2008; Walsh
et al., 2008; Schizophrenia Psychiatric Genome-Wide Association
Study (GWAS) Consortium, 2011; Lu et al., 2012; Wray et al.,
2012] strongly implicate VGCC signaling to be a shared neu-
robiological mechanism between these phenotypically divergent
illnesses.
The genetic and mechanistic evidence presented in this
review suggest that NOS1 may similarly play a role in multi-
ple psychiatric disorders. NOS1 activity is dependent on cal-
cium signaling mediated via calmodulin. This calcium signal-
ing may partially originate from L-type VGCCs. One study
found depolarization-stimulated and spontaneous cGMP for-
mation downstream of NOS1 activity to be blocked by the
L-type calcium channel blocker nifedipine (Oka et al., 1999).
Furthermore, there is evidence that NOS1, in turn, regulates
VGCCs including CACNA1C. The protein levels of CACNA1C
and CACNA1D were found to be signiﬁcantly reduced in the
cerebellum of Nos1 null mice (Kim et al., 2004). Together, these
data suggest that the potential involvement of NOS1 in multiple
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psychiatric disordersmay bemediated in part via interactions with
VGCCs.
The pursuit of convergent mechanisms in multiple psychiatric
disordersmay help identify points at which disease pathways inter-
sect and may lead to a more mechanistic nosology in psychiatry
beyond descriptive classiﬁcation. These studies are expected to
not only lead to conceptual advances in the neurobiology of psy-
chiatric disorders, but also to targets of molecular therapies with
widespread utility. In particular, because NO signaling has been
targeted pharmacologically for other indications, understanding
NOS1 dysfunction in psychiatric disorders has tremendous poten-
tial to lead to the repurposing of efﬁcacious, tested agents to treat
these disorders.
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